DaveFoster
Member
Dr. Peat has written about cortisol's ability to impair the liver's conversion of T4 to T3, and since elevated serotonin signals the ACTH to produce excess cortisol, it's no surprise that an anti-serotonin drug lowers cortisol and restores the endogenous conversion of T4 to T3.
Those who have elevated free T4 (FT4) as indicated by blood tests could benefit from an anti-serotonin drug, as such would allow for proper T4 conversion in the liver, and if adequately supported could result in an amplification of the pathways that detoxify estrogen from the body, which could lower cortisol even further in the long-term.
Further, Dr. Peat (and forum member haidut) have written extensively about the involvement of cortisol in depression, so it's not surprise that a drug (mirtazapine) that happens to lower cortisol has a superior record for treating major depressive disorder, panic disorder, and other mental disorders. It's also no surprise that the patients involved in this study had greater depression (as indicated by higher HAM-D scores) when their FT4 was highest. Lower FT4 resulted in decreased symptoms of depression, so there's a direct correlation between good thyroid function and happiness.
Effect of mirtazapine on thyroid hormones in adult patients with major depression. - PubMed - NCBI
Hypothalamic pituitary thyroid (HPT) axis abnormalities and alterations in major depression are reported in the literature. The aim of our study was to evaluate the effect of mirtazapine on thyroid hormones after 6 months of therapy in a sample of adult outpatients with Major Depression (MD). 17 adult outpatients (7 men, 10 women) with MD according to DSM-IV criteria, were included in the study. All participants had to have met criteria for a major depressive episode with a score of at least 15 on the Hamilton Depression Rating Scale (HAM-D). Fasting venous blood samples were obtained for determination of serum Thyroid Stimulating Hormone (TSH), Free T3 (FT3) and Free T4 (FT4) concentrations both at baseline and after 6 months of therapy. HAM-D scores decreased significantly from the first day of treatment to the end of the treatment period (P<0.001) and twelve patients (70.6%) were classified as responders. A significant increase in FT3 concentrations was found between baseline and the end of the treatment period (P=0.015), whereas FT4 concentrations decreased (P=0.046). No significant changes were found in TSH levels. Higher FT4 concentrations at baseline predicted higher HAM-D scorers both at baseline and at the end of the treatment period. Furthermore, higher FT3 concentrations at endpoint were found to be predictors of lower HAM-D scores. Long-term treatment with mirtazapine increases FT3 levels and decreases FT4 maybe involving the deiodination process of T4 into T3.
Those who have elevated free T4 (FT4) as indicated by blood tests could benefit from an anti-serotonin drug, as such would allow for proper T4 conversion in the liver, and if adequately supported could result in an amplification of the pathways that detoxify estrogen from the body, which could lower cortisol even further in the long-term.
Further, Dr. Peat (and forum member haidut) have written extensively about the involvement of cortisol in depression, so it's not surprise that a drug (mirtazapine) that happens to lower cortisol has a superior record for treating major depressive disorder, panic disorder, and other mental disorders. It's also no surprise that the patients involved in this study had greater depression (as indicated by higher HAM-D scores) when their FT4 was highest. Lower FT4 resulted in decreased symptoms of depression, so there's a direct correlation between good thyroid function and happiness.
Effect of mirtazapine on thyroid hormones in adult patients with major depression. - PubMed - NCBI
Hypothalamic pituitary thyroid (HPT) axis abnormalities and alterations in major depression are reported in the literature. The aim of our study was to evaluate the effect of mirtazapine on thyroid hormones after 6 months of therapy in a sample of adult outpatients with Major Depression (MD). 17 adult outpatients (7 men, 10 women) with MD according to DSM-IV criteria, were included in the study. All participants had to have met criteria for a major depressive episode with a score of at least 15 on the Hamilton Depression Rating Scale (HAM-D). Fasting venous blood samples were obtained for determination of serum Thyroid Stimulating Hormone (TSH), Free T3 (FT3) and Free T4 (FT4) concentrations both at baseline and after 6 months of therapy. HAM-D scores decreased significantly from the first day of treatment to the end of the treatment period (P<0.001) and twelve patients (70.6%) were classified as responders. A significant increase in FT3 concentrations was found between baseline and the end of the treatment period (P=0.015), whereas FT4 concentrations decreased (P=0.046). No significant changes were found in TSH levels. Higher FT4 concentrations at baseline predicted higher HAM-D scorers both at baseline and at the end of the treatment period. Furthermore, higher FT3 concentrations at endpoint were found to be predictors of lower HAM-D scores. Long-term treatment with mirtazapine increases FT3 levels and decreases FT4 maybe involving the deiodination process of T4 into T3.